Publications

S. pneumoniae Serotype Distribution and Antimicrobial Susceptibility Prior to and Post USA Introduction of 13-valent Pneumococcal Conjugate Vaccine, Lead author: Mendes RE, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Ceftriaxone Non-susceptibility in Emerging (35B) and Persisting (19A, 19F) S. pneumoniae Serotypes in the USA (2011 – 2012): Only Ceftaroline Retains Activity among &#223-lactams, Lead author: Mendes RE, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Genotypic Characterization of Methicillin-resistant Staphylococcus aureus Strains Recovered from Pneumonia Clinical Trials for Ceftobiprole, Lead author: Mendes RE, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Interim use of Vancomycin Susceptibility Testing Results to Predict Activity of Oritavancin, a New Long Acting Lipoglycopeptide, Lead author: Jones RN, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Re-evaluating the Contemporary (2007-2011) Spectrums of Tetracyclines (Minocycline, Doxycycline, and Tetracycline) Tested against Enterobacteriaceae and Acinetobacter spp., Lead author: Jones RN, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

In Vitro Activity Of The Novel Pleuromutilin BC-3781 Tested against Bacterial Pathogens Causing Sexually Transmitted Diseases, Lead author: Paukner, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Activity Activity of Cadazolid against Gram-positive Clinical Isolates, Including Linezolid-resistant Subsets with Defined Resistance Mechanisms, Lead author: Mendes RE, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Activity of ß-lactam Agents Tested in Combination with Novel &#223-lactamase Inhibitor Compounds against Enterobacteriaceae Producing Extended-spectrum ß-lactamases, Lead author: Mendes RE, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

ß-lactam Activity Tested in Combination with β-lactamase Inhibitor Candidates against Enterobacteriaceae Producing Class A, B and D Carbapenemases, Lead author: Mendes RE, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

In Vitro Activity of AZD0914: A New Benzisoxazole DNA Gyrase Inhibitor against Neisseria gonorrhoeae, Lead author: Huband, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Activity of the First-in-class Lpxc Inhibitor ACHN-975 and Comparators Tested against Gram-negative Organisms Including Isolates with Characterized Resistance Mechanisms, Lead author: Castanheira M, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Comparison of EUCAST and CLSI Broth Microdilution Methods for the Susceptibility Testing of 10 Systemically Active Antifungal Agents against Candida spp., Lead author: Castanheira M, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Intra- and Interlaboratory Study of Antifungal Susceptibility Testing of Isavuconazole against Aspergillus Strains, Lead author: Ghannoum, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Detection of fks Gene Hot Spot Mutations in Candida glabrata by CLSI Broth Microdilution Testing of Anidulafungin, Caspofungin and Micafungin using Epidemiological Cutoff Values, Lead author: Castanheira M, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Use of Micafungin as a Surrogate Marker to Predict Susceptibility and Resistance to Caspofungin among 3,747 Clinical Isolates of Candida using CLSI Methods and Interpretive Criteria, Lead author: Castanheira M, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Activity of Isavuconazole and Comparator Antifungals Tested against Contemporary (2012) Fungal Clinical Isolates Collected Worldwide, Lead author: Castanheira M, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

MALDI-TOF MS Identification of Clinically Significant Yeasts and Moulds in a Global Antifungal Surveillance Program, Lead author: Woosley LN, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Antimicrobial Activity of Ceftaroline and Comparator Agents against 6,502 S. pneumoniae Isolates from United States Medical Centers over 5 Years (2008-2012), Lead author: Sader HS, presented at American Thoracic Society (ATS), May 17 – 22, 2013, Philadelphia, PA

Prevelance of &#223-lactamase-encoding Genes in Escherichia coli Strains Collected in the USA: Report of the SENTRY Antimicrobial Susceptibility Program, Lead author: Castanheira M, presented at 113th annual American Society for Microbiology General Meeting (ASM), May 18 – 21, 2013, Denver, CO

Comprehensive Update of Dalbavancin Activity when Tested against Uncommonly Isolated Streptococci, Corynebacterium spp., Listeria monocytogenes and Micrococcus spp., Lead author: Jones RN, presented at 113th annual American Society for Microbiology General Meeting (ASM), May 18 – 21, 2013, Denver, CO

Clonal expansion of Acinetobacter baumannii strains displaying elevated tigecycline minimum inhibitory concentration (MIC) values responsible for increasing resistance rates in Latin America (eposter), Lead author: Castanheira M, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Antimicrobial activity of ceftolozane/tazobactam tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in European hospitals (2011) (oral), Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Molecular characterisation of Staphylococcus aureus isolates that are non-susceptible to ceftaroline isolated during the 2010 surveillance programme (oral), Lead author: Alm, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Is what you see what you get? Product variation in clinical and reference formulations of polymyxin B, Lead author: Kassamali, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Characterisation of three new VIM enzymes, VIM-35, VIM-36 and VIM-37 identified in European countries: report of the SENTRY Antimicrobial Surveillance Programme, Lead author: Castanheira M, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Beta-lactamase production among ceftazidime-resistant Pseudomonas aeruginosa from five European countries: high prevalence of oxacillinases and VIM enzymes in the SENTRY Programme, Lead author: Castanheira M, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

AmpC and MexAB-OprM hyperexpression are most common mechanisms among ceftazidime- and imipenem-resistant Pseudomonas aeruginosa from Chinese hospitals, Lead author: Castanheira M, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Detection of plasmid-encoded CFR in clinical isolates of Enterococcus faecalis from Panamá City: report from the SENTRY Antimicrobial Surveillance Programme, Lead author: Mendes RE, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Susceptibility rates in Latin American nations: report from the Emerging Markets Resistance Surveillance Programme, Lead author: Jones RN, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Resistance surveillance programme report for European nations (2011), Lead author: Jones RN, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Longitudinal assessment of tigecycline activity tested against Gram-positive and Gram-negative organisms from European medical centres: results from the SENTRY Programme (2004-2012), Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Antimicrobial susceptibility of Gram-negative bacteria causing urinary tract infections in European and United States hospitals (2009-2011), Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Screening for fluoroquinolone-resistance in staphylococcus aureus and Streptococcus spp using norfloxacin and EUCAST disc diffusion criteria, Lead author: Ahman, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Improved screen for beta-lactam-resistance in Streptococcus pneumoniae with the oxacillin 1-ug disk using the EUCAST disc diffusion method, Lead author: Matuschek, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Biapenem and biapenem/RPX7009 MIC quality control ranges using CLSI multi-laboratory M23-A3 study design, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Activity of aztreonam combined with the beta-lactamase inhibitor avibactam tested against metallo beta-lactamase-producing organisms, Lead author: Castanheira M, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Antimicrobial activity of ceftaroline and comparator agents tested against organisms causing skin and soft tissue infections in European medical centres (2011), Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Antimicrobial activity of ceftaroline combined with avibactam tested against contemporary (2012) bacteria collected from USA patients with acute bacterial skin and skin structure infections, Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Ceftaroline activity tested against uncommonly isolated Gram-positive pathogens (2008-2011), Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Activity of ceftaroline against the leading community-acquired respiratory tract infection pathogens in Europe and the Mediterranean region, 2011, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Activity of ceftobiprole tested against pathogens associated with hospital-acquired bacterial pneumonia in Europe, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Activity of ceftobiprole tested against pathogens associated with community-acquired bacterial pneumonia in Europe, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Activity of ceftobiprole tested against Gram-negative clinical isolates from European medical centres, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Activity of ceftobiprole tested against clinical isolates of staphylococci and streptococci from European surveillance (2008-2010), Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus including strains with reduced susceptibility to daptomycin, linezolid, and vancomycin, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Antimicrobial activity of ceftolozane/tazobactam and comparator agents tested against Pseudomonas aeruginosa isolates from 14 European countries and Israel, Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Oritavancin activity tested against Staphylococcus aureus and beta-haemolytic streptococci causing skin and soft tissue infections in the European Union and other countries (2010-2012), Lead author: Mendes RE, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Assessment of oritavancin activity tested against contemporary clinical isolates responsible for documented bacteremia in the European Union and other countries (2010-2012), Lead author: Mendes RE, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Dalbavancin activity in the USA: reported from the SENTRY Programme (2012), Lead author: Jones RN, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany

Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model, Lead author: Bhavnani, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany